10 August 2018
Visiongain has launched a new pharma report Global Treatment for Neglected Tropical Disease Market 2017-2027: Malaria, Dengue, Leishmaniasis, Schistosomiasis, Lymphatic Filariasis, Chagas Disease
According to the Centers for Disease Control and Prevention (CDC), one hundred percent of low-income countries are affected by at least five neglected tropical diseases simultaneously. Worldwide, 149 countries and territories are affected by at least one neglected tropical disease (NTD). The disease burden, however, is not restricted to these areas since vectors and parasites can often spread to other regions via travellers or cargo. Every year, malaria alone results in one to three million deaths out of approximately half a billion cases, while many more go undetected or undiagnosed.
The lead analyst of the report commented “The treatment for neglected tropical disease market is set to experience considerable growth over the next decade. The main growth drivers include, rising awareness towards neglected tropical disease, increasing prevalence of neglected disease such as malaria and dengue as well as increasing governments’ initiatives.
There are still gaps that need to be met. Improved diagnostics for neglected tropical diseases for example, are essential for guiding treatment strategies at different thresholds of control, interruption of transmission, elimination and post-elimination surveillance.”
Leading companies featured in the report include Pfizer, Inc., Bayer, GlaxoSmithKline plc, Merck & Co., Inc., Novartis International AG, Takeda Pharmaceutical Company Ltd, Sanofi S.A. and Eisai Co., Ltd.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.
12 April 2021
Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.
09 April 2021
The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.
06 April 2021
Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth.